<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cannabinoid compounds have been shown to exert anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects by affecting <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, invasion, and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we examined the action mechanism by which LYR-8, a novel hexahydrocannabinol analog, exerts anti-angiogenic and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> xenografts </plain></SENT>
<SENT sid="2" pm="."><plain>In the xenografted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues, LYR-8 significantly reduced the expression of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1 alpha (HIF-1α), a transcription factor responsible for induction of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>-promoting factors, and its target genes, vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) </plain></SENT>
<SENT sid="3" pm="."><plain>In HT-29 human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells treated with a <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducing agent (CoCl(2)), LYR-8 dose-dependently suppressed the induction of HIF-1α and subsequently its targets, VEGF and COX-2 </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, highly elevated <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) (<z:chebi fb="0" ids="26338">PGE</z:chebi>(2)) concentrations in CoCl(2)-treated HT-29 cells were also significantly suppressed by LYR-8 </plain></SENT>
<SENT sid="5" pm="."><plain>However, LYR-8 alone in the absence of CoCl(2) did not alter the basal expression of VEGF and COX-2, or <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) production </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, LYR-8 effectively suppressed Akt signaling, which corresponded to the suppression of CoCl(2)-induced HIF-1α accumulation </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, LYR-8 exerts anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects through the inhibition of Akt and HIF-1α activation, and subsequently suppressing factors regulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment, such as VEGF and COX-2 </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate a novel function of cannabinoid-like compound LYR-8 as an anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> agent with a HIF-1α inhibitory activity </plain></SENT>
</text></document>